Abstracts tagged "IL-6"

Abstract Number: 1581 • 2016 ACR/ARHP Annual Meeting
The Combination of IL-6 and IL-6 Receptor Levels As a Biomarker of Response to Tocilizumab in Rheumatoid Arthritis Patients
Cesar Diaz-Torne¹, Maria A. Ortiz², Patricia Moya³, M. Victoria Hernández⁴, Delia Reina⁵, Ivan Castellvi⁶, Juan Jose De Agustin⁷, Diana De La Fuente⁸, Hector Corominas^9,10, Raimon Sanmarti¹¹, Josep Maria De Llobet Zubiaga¹ and Silvia Vidal², ¹Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, ²Institut de Recerca Sant Pau, Barcelona, Spain, ³Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ⁵Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ⁶Rheumatology, Hospital de Sant Pau, Barcelona, Spain, ⁷Rheumatology, Hospital Baix de Llobregat, Barcelona, Spain, ⁸Rheumatology, Hospital de Viladecans, Barcelona, Spain, ⁹Rheumatology, Hospital Moises Broggi, Barcelona, Spain, ¹⁰Servei de Reumatologia, Hospital Moises Broggi, Barcelona, Spain, ¹¹Arthritis Unit. Rheumatology, Arthritis Unit. Rheumatology Department. Hospital Clínic, Barcelona, Spain
Background/Purpose: Several predictors of response to tocilizumab have been described. They include a low HAQ, high baseline CRP or NK levels and certain IL-6R polymorphisms.…
Abstract Number: 1598 • 2016 ACR/ARHP Annual Meeting
Olokizumab Treatment of Both Western and Asian Patients with Rheumatoid Arthritis Who Have Failed Anti-TNF Treatment Results in Sustained Improvements in Patient-Reported Outcomes
Mark C. Genovese¹, Patrick Durez², Roy Fleischmann³, Yoshiya Tanaka⁴, Daniel E. Furst⁵, Hisashi Yamanaka⁶, Igor Vasyutin⁷, Thangavel Kaviarasu⁸, Elena Korneva⁷, Dmitry Koloda⁷ and Tsutomu Takeuchi⁹, ¹Stanford University Medical Center, Palo Alto, CA, ²Department of Rheumatology, Université Catholique de Louvain, Brussels, Belgium, ³Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ⁵David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁶Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁷R-Pharm CJSC, Moscow, Russian Federation, ⁸Quintiles Inc, Mumbai, India, ⁹School of Medicine, Keio University, Tokyo, Japan
Background/Purpose: Rheumatoid arthritis (RA) has a high patient (pt) burden with significant impact on health-related quality of life. We report the effect of treatment with…
Abstract Number: 1607 • 2016 ACR/ARHP Annual Meeting
The Development of a New Anti–Interleukin 6 Blocker for Rheumatoid Arthritis Patients
Alan Glicklich¹, Paul Grayson¹, Christophe Blanchetot², Qing Zhou³ and Anke Kretz-Rommel¹, ¹Bird Rock Bio, Inc, La Jolla, CA, ²Argenx, Ghent, Belgium, ³Genor BioPharma, Shanghai, China
Background/Purpose: While interleukin-6 (IL-6) blockade with monoclonal antibodies is an established, clinically validated mechanism for the treatment of rheumatoid arthritis (RA), the need for significant…
Abstract Number: 1615 • 2016 ACR/ARHP Annual Meeting
Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, Significantly Improves Physical Function and Reduces Morning Stiffness in Patients with Active Rheumatoid Arthritis Despite Anti-TNF Therapy: Results from a Global, Randomized, Placebo-Controlled, Phase 3 Trial
Yoshiya Tanaka¹, Clifton Bingham III², Daniel Aletaha³, Prasheen Agarwal⁴, Sharon Popik⁴, Regina Kurrasch⁵, Steve Peterson⁴, Rita Ganguly⁵, Chenglong Han⁴ and Kelly McQuarrie⁴, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵GlaxoSmithKline, Collegeville, PA
Background/Purpose: Improvement in physical function and morning stiffness are key goals of rheumatoid arthritis (RA) treatment. Sirukumab, a selective human anti–IL6 monoclonal antibody, has recently…
Abstract Number: 1625 • 2016 ACR/ARHP Annual Meeting
Analysis of a Phase 3 Study Evaluating the Efficacy of Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, Across Subgroups in Patients with Active Rheumatoid Arthritis Despite Treatment with Disease-Modifying Anti-Rheumatic Drugs
Carter Thorne¹, George Karpouzas², Tsutomu Takeuchi³, Shihong Sheng⁴, Weichun Xu⁴, Ravi Rao⁵, Kaiyin Fei⁴ and Benjamin Hsu⁴, ¹University of Toronto and Southlake Regional Health Centre, Newmarket, ON, Canada, ²Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ³Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom
Background/Purpose: Sirukumab is a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, and is under development for rheumatoid arthritis (RA)…
Abstract Number: 1986 • 2015 ACR/ARHP Annual Meeting
Clinical Efficacy of Tocilizumab in Polymyalgia Rheumatica: An OPEN-Label Study.
Eric Toussirot¹, Antoine Martin², Martin Soubrier³, serge redeker⁴, Alexis Régent⁵ and Le CRI⁶, ¹Service de Rhumatologie, CHU J Minjoz, Besancon, France, ²Rheumatology, Centre Hospitalier, St Brieuc, France, ³Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁴43 rue de l'isle, Ch Abbeville, Abbeville, France, ⁵Paris Descartes University, UPRES-EA 4058, Paris, France, ⁶Rheumatology, CHU, Strasbourg, France
Background/Purpose: polymyalgia rheumatic (PMR) is a chronic inflammatory disorder of unknown etiology that affects elderly people. Glucocorticoids (GC) are still the mainstay of therapy for…
Abstract Number: 2017 • 2015 ACR/ARHP Annual Meeting
DNA Methylation Governs the Ability of Apoptotic Cells to Suppress Inflammatory Arthritis Via Reciprocal Regulation of IL-6 and TGF-Beta
Clare Notley¹, Christine Jordan², Jenny McGovern², Mark Brown² and Michael R. Ehrenstein³, ¹Rheumatology, UCL, London, United Kingdom, ²UCL, London, United Kingdom, ³Medicine, University College London, London, United Kingdom
Background/Purpose: Apoptotic cells (AC) have potent anti-inflammatory effects. Injection of apoptotic dendritic cells into mice suppresses the severity of antigen-induced arthritis through increased TGFβ production…
Abstract Number: 2571 • 2015 ACR/ARHP Annual Meeting
Anti-IL-6 Receptor Antibody Prevents Loss of Bone Strength in a Mouse Model of Collagen-Induced Arthritis
Hiroto Yoshida, Yuanyuan Bi, Miho Suzuki, Keisuke Tanaka and Yoshihiro Matsumoto, Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a disease that typically induces secondary osteoporosis, which increases the risk of bone fractures and, consequently, mortality. Bone fracture is…
Abstract Number: 2947 • 2015 ACR/ARHP Annual Meeting
Association of Anti-NR2 and U1RNP Antibodies with Neurotoxic Inflammatory Mediators in Cerebrospinal Fluid from Patients with Neuropsychiatric Systemic Lupus Erythematosus
Seiko Kondo-Ishikawa¹, Takao Fujii², Nozomi Ishigooka¹, Kosaku Murakami¹, Ran Nakashima¹, Yoshitaka Imura¹, Motomu Hashimoto², Naoichiro Yukawa¹, Hajime Yoshifuji¹, Koichiro Ohmura¹ and Tsuneyo Mimori¹, ¹Department of Rheumatology and Clinical Immunology, Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Department of the Control for Rheumatic Diseases, Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Background/Purpose: Autoantibodies (auto Abs) in cerebrospinal fluid (CSF) and inflammatory mediators (IMs) may be involved in the pathogenesis of neuropsychiatric systemic lupus erythematosus (NPSLE). Previous…
Abstract Number: 3145 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Modified-Release Prednisone in Patients with Polymyalgia Rheumatica: Results of a Multicenter, Randomized, Active-Controlled Phase 3 Study
Maurizio Cutolo¹, Michael Hopp², Stefan Liebscher², Bhaskar Dasgupta³ and Frank Buttgereit⁴, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, ²Medical Science, Mundipharma Research GmbH & Co. KG, Limburg, Germany, ³Rheumatology, Southend University Hospital, Essex, United Kingdom, ⁴Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Polymyalgia rheumatica (PMR) is characterized by persisting proximal pain and morning stiffness of the neck, shoulder and hip girdles of 2 weeks' duration, an…
Abstract Number: 200 • 2015 ACR/ARHP Annual Meeting
Mast Cell Regulation of Aortic IL-6 Expression Involves Histamine-1 Receptor, Suppressor of Cyotkine Signaling-1 and IL-10
Vineesh Raveendran¹, Jason Springer², Donald Smith³, Mehrdad Maz⁴ and Kottarappat Dileepan¹, ¹Department of Medicine, University of Kansas Medical Center, Kansas City, KS, ²Division of Allergy, Clinical Immunology and Rheumatology, University of Kansas Medical Center, Kansas City, KS, ³University of Kansas Medical Center, Kansas City, KS, ⁴Division of Rheumatology, University of Kansas Medical Center, Kansas City, KS
Background/Purpose: IL-6 plays an important role in the pathogenesis of large vessel vasculitis. Lipopolysaccharide (LPS), acting through toll-like receptor 4, enhances both the aortic expression…
Abstract Number: 253 • 2015 ACR/ARHP Annual Meeting
Multiple Serum Cytokine Profiling to Identify Specific Molecular Networks in Attacks of Familial Mediterranean Fever
Tomohiro Koga¹, Kiyoshi Migita², Shuntaro Sato³, Masataka Umeda⁴, Shoichi Fukui⁵, Ayako Nishino⁴, Shinya Kawashiri⁶, Naoki Iwamoto⁵, Kunihiro Ichinose⁵, Mami Tamai⁵, Hideki Nakamura⁵, Tomoki Origuchi⁷, Yukitaka Ueki⁸, Kazunaga Agematsu⁹, Katsumi Eguchi¹⁰ and Atsushi Kawakami⁴, ¹Departments of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Japan, ³Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan, ⁴Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, ⁵Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁶Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁷Department of Rehabilitation Sciences, Nagasaki University, Nagasaki, Japan, ⁸Rheumatic and Collagen Disease Center, Sasebo Chuo Hospital, Sasebo, Japan, ⁹Department of Infectious Immunology, Shinshu University, Graduate School of Medicine, Shinshu, Japan, ¹⁰Department of Rheumatology, Sasebo Chuo Hospital, Sasebo, Japan
Background/Purpose: Familial mediterranean fever (FMF) is caused by a number of mutations of the MEFV gene, coding for a protein named pyrin that acts as…
Abstract Number: 798 • 2015 ACR/ARHP Annual Meeting
Keratinocyte-Associated IL-6 Is Elevated in Cutaneous Lupus Rashes and Production of IL-6 By Keratinocytes Is Enhanced in Non-Involved Lupus Skin
Jasmine Stannard¹, Emily Myers², Tamra J. Reed³, Lori Lowe⁴ and J. Michelle Kahlenberg⁵, ¹Int. Medicine/Rheumatology, University of Michigan, Ann Arbor, MI, ²Georgetown University, Washington, DC, ³Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI, ⁴Dermatology, University of Michigan, Ann Arbor, MI, ⁵Internal Medicine, Division of Rheumatology, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Systemic lupus erythematosus (SLE) is a devastating autoimmune disease with severe complications such as immune-complex mediated nephritis and scarring skin lesions. Treatment modalities for…
Abstract Number: 1153 • 2015 ACR/ARHP Annual Meeting
Colonic Intraepithelial Lymphocytes Produce IL-6 in Response to Resident Bacteria to Modulate Epithelial Barrier Function
Gaurav Mehta¹, Emilie H. Regner², Neha Ohri², Sean P. Colgan² and Kristine A. Kuhn², ¹Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ²University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Dysbiosis of colon bacteria has emerged as a likely contributor to diseases such as rheumatoid arthritis and spondyloarthropathies. Interactions between the microbiota and distal…
Abstract Number: 1405 • 2015 ACR/ARHP Annual Meeting
Tocilizumab Serum Levels and Antidrug Antibodies and Its Relationship with Disease Activity in Rheumatic Diseases
Samantha Rodriguez-Muguruza¹, Melania Martínez-Morillo¹, Juana Sanint², Bibiana Quirant Sr.³, Aina Teniente Sr.⁴, Agueda Prior⁵, Anne Riveros-Frutos⁶, Susana Holgado⁷, Maria Lourdes Mateo⁷, Alejandro Olivé⁸, Jeronima Cañellas⁵ and Xavier Tena⁷, ¹Rheumatology, Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, ²Rheumatology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ³Immunology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ⁴immunology, Hospital Universitari Germans Trias i Pujol, barcelona, Spain, ⁵Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ⁶Microbiology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ⁷Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ⁸Hospital Germans Trias i Pujol, Badalona, Spain
Background/Purpose: Tocilizumab (TCZ) is a humanized anti-IL-6 receptor-blocking monoclonal antibody used for the treatment of rheumatoid arthritis (RA), idiopathic juvenile arthritis (IJA) and off-label in…

« Previous Page
1
…
3
4
5
6
7
…
9
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].